Drug – bio-affecting and body treating compositions – Conjugate or complex of monoclonal or polyclonal antibody,... – Conjugated via claimed linking group – bond – chelating agent,...
Patent
1997-03-21
1999-07-06
Reeves, Julie
Drug, bio-affecting and body treating compositions
Conjugate or complex of monoclonal or polyclonal antibody,...
Conjugated via claimed linking group, bond, chelating agent,...
4241551, 4241831, 5303888, 5303917, A61K 39395
Patent
active
059194561
ABSTRACT:
This invention provides chimeric molecules useful for killing tumor cells bearing IL13 receptor(s) (IL-13R). The molecules comprise a cytotoxic molecule attached to a targeting molecule that specifically binds an IL-13 receptor. Preferred targeting molecules include IL-13 and anti-IL-13R antibodies.
REFERENCES:
patent: 5082927 (1992-01-01), Pastan et al.
patent: 5596072 (1997-01-01), Culpepper et al.
patent: 5614191 (1997-03-01), Puri et al.
EMBO Journal, vol. 12, No. 7, 1993, Eynsham, Oxford GB, pp. 2663-2670, XP002011860 S. M. Zurawski et al: "Receptors for Interleukin-13 and Interleukin-4 are complex and share a novel component that functions in signal transduction".
Journal of Biological Chemistry, vol. 270, No. 28, 14 Jul. 1995, MD US, pp. 16775-16780, XP002011861 W. Debinski et al: "A novel chimeric protein composed of Interleukin-13 and Pseudomonas Exotoxin is highly cytotoxic to human carcinoma cells expressing receptors for Interleukin-13 and Interleukin-4".
Chaudhary et al., Nature, 339: 394-397 (1989).
Chester et al., Tibtec 13: vol. 13, 294-300 (1995).
Debinski et al., J. Biol Chem, vol. 268, 19:14065 (1993).
Debinski et al., Biocanjugate Chem, vol. 5, 40-46 (1994).
Gottstein et al., Annab of Oncology, vol. 5 Supplement 1 S97-103 (1994).
McKenzie et al. Proc. Natl. Acad. Sci. USA, 90: 3735 (1993).
Obiri et al., J. Biol. Chem., vol. 270, 15:8797 (1995).
Pastan et al., Ann. Rev. Biochem., 61: 331-354 (1992).
Minty et al., Nature, 362: 248 (1993).
Vita et al., Journ. of biol. Chem., 270:3512 (1995).
Thrush et al., Ann Rev Immunol., vol. 14, 49-71 (1996).
Paul Fundamental Immunology Third Edition 784-789, 1993.
Puri et al Blood vol 87 No. 10 4333-4339, May 1996.
Debinski Waldemar
Obiri Nicholas
Pastan Ira
Puri Raj K.
Reeves Julie
The United States of America as represented by the Secretary of
LandOfFree
IL-13 receptor specific chimeric proteins does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with IL-13 receptor specific chimeric proteins, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and IL-13 receptor specific chimeric proteins will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-897292